RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants by Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD

Get full text

An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study by Po-Lan Su, MD, Gee-Chen Chang, MD, Shih-Hsin Hsiao, MD, Te-Chun Hsia, MD, Meng-Chih Lin, MD, Min-Hsi Lin, MD, Jin-Yuan Shih, MD, Cheng-Ta Yang, MD, Sheng-Hsiung Yang, MD, Yuh-Min Chen, MD, PhD

Get full text

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan by Shang-Gin Wu, MD, PhD, Wei-Yu Liao, MD, PhD, Kang-Yi Su, PhD, Sung-Liang Yu, PhD, Yen-Lin Huang, MD, Chong-Jen Yu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jin-Yuan Shih, MD, PhD

Get full text

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC by Bin-Chi Liao, MD, Wei-Hsun Hsu, MD, Jih-Hsiang Lee, MD, Ching-Yao Yang, MD, PhD, Tzu-Hsiu Tsai, MD, PhD, Wei-Yu Liao, MD, PhD, Chao-Chi Ho, MD, PhD, Chia-Chi Lin, MD, PhD, Jin-Yuan Shih, MD, PhD, Chong-Jen Yu, MD, PhD, Ross A. Soo, M.B.B.S., James Chih-Hsin Yang, MD, PhD

Get full text